Fox Chase Cancer Center's Eric M. Horwitz Elected Vice President of the American Brachytherapy Society
PHILADELPHIA (May 5, 2008)— Eric M. Horwitz, MD - Chair, Radiation Oncology; Gerald E. Hanks Chair in Radiation Oncology, vice chairman and clinical director of the radiation oncology department at Fox Chase Cancer Center, has been elected vice-president (president-elect) of the American Brachytherapy Society (ABS). Horwitz will serve a one year term and, most recently, served as the society's treasurer.
The ABS, founded in 1978, serves its members by advancing the field of brachytherapy. The society promotes excellence in education, research and clinical practice. Brachytherapy is currently used to treat prostate, breast and cervical cancers.
Horwitz is recognized nationally for his expertise in treating patients with prostate cancer. At Fox Chase, he has developed advanced programs using intensity-modulated radiation therapy (IMRT), image-guided radiation therapy and brachytherapy. These include high-dose-rate (HDR) brachytherapy for prostate cancer, a treatment using temporary radiation implants. As a result, Fox Chase was the first institution in the Northeast United States to offer HDR implants to men with prostate cancer.
In addition, Horwitz integrated the use of an MRI treatment simulator into prostate cancer treatment planning for both permanent, low-dose prostate implants and external radiation therapy. Fox Chase was the first in the world to use MRI in radiation treatment planning.
Horwitz has published extensively in peer-reviewed journals and is a co-author of several chapters in various oncology texts. He has been invited to give numerous lectures and presentations at professional meetings in the United States and abroad.
Horwitz, of Blue Bell, Pa., joined Fox Chase in 1997. He was named clinical director of radiation oncology in 2003 and appointed vice chairman in 2007. He serves on the editorial board of the journal Brachytherapy. He is also active in the American Society of Therapeutic Radiology and Oncology and the American College of Radiology.
Horwitz received his M.D. from Albany Medical College in New York after earning his undergraduate degree at the University of Pennsylvania in Philadelphia. He completed both his internship and residency at William Beaumont Hospital in Royal Oak, Mich. He was chief resident in radiation oncology there before he came to Fox Chase in 1997. In 2003, he was promoted from associate member to member with tenure in Fox Chase's division of medical science.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.